Dihydroartemisinin enhances remyelination by switching microglia to the reparative phenotype.

ABSTRACT:

Background

Boosting myelin repair is widely recognized as one of the most powerful approaches for demyelinating therapy, essentially contributing to the recovery of neurological functions. Maintaining immune homeostasis in microglia is a prerequisite for creating a reparative environment for myelin. Dihydroartemisinin (DHA) is clinically effective in reshaping immunological status and implies potential in treating demyelinating disease. However, its relevance to pro-remyelination remains unclear.

Methods

We first evaluated the effects of DHA on neurofunctional recovery and white matter integrity in chronic experimental autoimmune encephalomyelitis (EAE), an ideal model for secondary progressive multiple sclerosis (SPMS) characterized by remyelination deficiency. Single-cell

SUBMITTER: Liu L 

PROVIDER: S-EPMC12317512 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature